Cytodyn Inc (CYDY)

[Monroe1]

a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the formation and initial members of its Scientific Advisory Board today including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers.

Just take Rheumatology. These other indications are going to take us from profits bigly to profits Super Sized. Think about the market size of folks suffering from arthritis and MS and Lupus.

The company will have to do some spin offs. The company will be doing some forward splits. Guaranteed. The patents we hold have a greater value than pure gold on steroids, plasma, ramitsevere, and all the other FDA BS combined times 1000. Do your research. Know what you own.

We are getting tightly wound and gearing for a heavy run.